Products of gynaecological neoplasms: clinical and pathological applications
- PMID: 6158296
- DOI: 10.1007/BF02108582
Products of gynaecological neoplasms: clinical and pathological applications
Abstract
Alphafetoprotein is at present the only 'antigen' of proved clinical value in gynaecological neoplasia. Its synthesis and release by a particular type of germ cell tumour (yolk sac, endodermal sinus tumour) present alone or as part of a teratoma approaches many of the essential criteria of a utopian tumour marker. Unfortunately, none of the other recognised 'antigens' expressed and/or released by gynaecological tumours and which have been adequately assessed in the clinical situation, seem to represent laboratory adjuncts essential for adequate patient care at present. Further research is needed to define other factors if this approach to improving diagnosis and management is to succeed.
Similar articles
-
Biochemical markers in gynaecological cancer.Ir Med J. 1980 Aug;73(8):285-6. Ir Med J. 1980. PMID: 6161106 No abstract available.
-
Tumour markers in gynaecologic oncology.Scand J Clin Lab Invest Suppl. 1991;206:60-70. Scand J Clin Lab Invest Suppl. 1991. PMID: 1719611 Review.
-
Clinical use of gynaecologic tumour markers.Ann Chir Gynaecol. 1989;78(1):65-70. Ann Chir Gynaecol. 1989. PMID: 2547331 Review.
-
[Monitoring the course of malignant neoplasms of the genital organs in women by means of determination of blood serum level of fucose, sialic acid, CEA and AFP].Ginekol Pol. 1979 Dec;50(12):1029-36. Ginekol Pol. 1979. PMID: 94024 Polish. No abstract available.
-
Biochemical markers in ovarian cancer: possibilities and limitations.Ann Clin Biochem. 1982 Jul;19 (Pt 4):258-62. doi: 10.1177/000456328201900414. Ann Clin Biochem. 1982. PMID: 6751203 Review.